Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

18.29 -0.02 (-0.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
From Novocure
Via Business Wire
Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
From Novocure
Via Business Wire
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
From Novocure
Via Business Wire
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
From Novocure
Via Business Wire
Novocure Secures CE Mark for New Array
From Novocure
Via Business Wire
Novocure Reports Third Quarter 2022 Financial Results
From Novocure
Via Business Wire
Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting
From Novocure
Via Business Wire
Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology
From Novocure
Via Business Wire
Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy
From Novocure
Via Business Wire
Novocure to Report Third Quarter 2022 Financial Results
From Novocure
Via Business Wire
Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business
From Novocure
Via Business Wire
Novocure to Participate in Upcoming Investor Conferences
From Novocure
Via Business Wire
Novocure Hosts U.S. Sen. Maggie Hassan at Company’s Portsmouth Facility
From Novocure
Via Business Wire
Novocure Reports Second Quarter 2022 Financial Results
From Novocure
Via Business Wire
Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
From Novocure
Via Business Wire
Novocure to Report Second Quarter 2022 Financial Results
From Novocure
Via Business Wire
Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
From Novocure
Via Business Wire
Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma
From Novocure
Via Business Wire
Novocure Reports First Quarter 2022 Financial Results
From Novocure
Via Business Wire
Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu
From Novocure
Via Business Wire
Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields
From Novocure
Via Business Wire
Novocure to Report First Quarter 2022 Financial Results
From Novocure
Via Business Wire
Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial
From Novocure
Via Business Wire
Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer
From Novocure
Via Business Wire
Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation
From Novocure
Via Business Wire
Novocure’s General Counsel Resigns After 10 Years of Service
From Novocure
Via Business Wire
New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response
From Novocure
Via Business Wire
Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provides Company Update
From Novocure
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback